

# Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer

*Jason D. Wright, MD, Yongemei Huang,  
MD/PhD, William M. Burke, MD, et al.*

Journal Club  
March 16, 2016  
Blaine Campbell-PGY2

# Objective

- To use a number of methods to control for confounding and selection bias to examine the association between lymphadenectomy (LAD) and survival in a large cohort of women with endometrial cancer



OBSTETRICS & GYNECOLOGY

## OBSTETRICS & GYNECOLOGY

Volume 127, Number 5, May 2018



FEATURED ARTICLES	
Less is More: The Changing Landscape of Our Patients	475
Evaluation and Management of Women and Menstrual Health: A Multidisciplinary Approach	478
Comparison of Women in Department Laboratories in Obstetrics and Gynecology with Those in Other Specialties	482
Trends in Pelvic Surveillances: Finding for Early Stage Ovarian Cancer	488
Cervical Cancer Screening	498
Advocates to Reduce Sleep Disruption in Perinatal and Postpartum Women: A Systematic Review and Meta-analysis	503
Women's Perineal Sexual Health, Postnatal Trauma, Psychological Symptoms, and Perceived Social Exclusion	518
Severe Maternal Morbidity and the Use of Fetal Monitoring: A Retrospective Cohort Study	527

PHOTO: JEFFREY M. HARRIS, MD

# History

# History

- Endometrial Adenocarcinoma
  - 1980s: intracavitary radiation
  - Later: primary surgery with lymph node sampling of high risk patients
  - (+) nodes → pelvic radiation
- Observational studies demonstrated therapeutic benefit for LAD, even if no nodal mets
  - Sampling of nodes → full LAD of pelvic/paraaortic

# History

- Two European RCTs (2008, 2009)
  - No association between LAD and survival
  - ? Power
  - ? Quality of dissection
  - ? Ability of nodal status to guide therapy

# Materials and Methods

# Materials and Methods

- Retrospective Cohort Study using the *National Cancer Data Base*
  - Endometrioid Adenocarcinoma
  - Hysterectomy +/- lymphadenectomy 1998-2011
- Variety of statistical methodologies now available to control for measured and unmeasured confounders

# Materials and Methods

- Retrospective cohort study
  - 1500 Commission on Cancer-affiliated hosp
  - Total of 151,089 women
- Data collected on:
  - Pt demographics
  - Clinical data
  - Tumor characteristics
  - Staging
  - Treatment
  - Overall survival

# Materials and Methods

- Exclusion criteria
  - Preoperative radiation
  - Primary tumor before diagnosis of uterine cancer
  - Spread of tumor beyond uterus (>T2) or metastasis
- Inclusion criteria
  - Hysterectomy +/- LAD (regardless of nodal status)
  - LN dissection = *any* LN

# Grouping

- Staging system
  - Study spanned the American Joint Commission on Cancer staging systems 5-7
    - Converted T stage to uniform nomenclature
    - T1A (limited to endometrium or <50% myometrium)
    - T1B (>50% myometrial invasion)
    - T2 (cervical stromal involvement)
- Other divided groups
  - >/< 10 (+) nodes, age, race, insurance, region of residence, level of education, tumor grade, use of adjuvant radiotherapy, hospital type, mean annual number of cases per hospital

# Statistical Factors

- Propensity Score Analysis
- Instrumental Variable Analysis
- Cox Proportional Hazards Analysis & Regression Models
- Greedy 5:1 digit matching algorithm
- Poisson Distribution/Multivariable distribution
- Two-stage residual inclusion methodology
- Logistic Regression Model

# Propensity Score Analysis

*“...the predicted probability of treatment.”*

- To calculate:
  - Logistic regression model that included all clinical, oncologic, and hospital characteristics to determine the probability of undergoing LAD
- Marginal Cox proportional hazards regression models were used to estimate the HR of mortality with receipt of LAD accounting for hospital clustering

# Instrumental Variable Analysis

*“...an analytic methodology that attempts to adjust for measured and unmeasured confounders through application of an exogenous instrument.”*

- “Instrument” = characteristic assoc with treatment but not outcome
- In this study, the instrument = geographic variation
- Provide pseudorandomization to help control for unmeasured confounding

# Models

- Created 2 different methods
  - Propensity score
  - Instrumental variable analysis
- For each methodology, they developed a model to include:
  - Only LAD
  - LAD and all patient & hospital characteristics
  - All the variables in the clinical model as well as adjuvant therapy


# Results

# Results

151,089 women  
(1998-2011)

99,052 (65.6%)  
LAD

52,037 (34.4%)  
No LAD



Overall rate of LAD:  
T1A = 60.7%  
T1B = 78.7%  
T2 = 77.9%

51.8% - 70.6%

# Results

- Regression model adjusted for clinical characteristics (Propensity score, matching, or inverse probability tx):
  - *16% reduction* of mortality (HR 0.84, 95% CI 0.81-0.87)
  - Similar when adjusted for adjuvant therapy (HR 0.85, 95% CI 0.82-0.87)
- Instrumental variable analysis:
  - No statistically significant assoc between LAD and survival (HR 0.75, 95% CI 0.53-1.06)
  - Similar after adjustment for adjuvant therapy (HR 0.76, 95% CI 0.54-1.06)

# Results

- Stratified by T stage for T1A/T1B:
  - Propensity score models suggested reduced mortality with LAD
  - Instrumental variable analysis found no statistically significant association between LAD and survival
- All the modalities found decreased mortality in women with T2 tumors who underwent LAD

# Results

- When limited to only women who underwent LAD, comparing # nodes (<10 nodes, >10 nodes)
  - Instrumental variable analysis demonstrated no association between patients with T1A/T1B tumors

# Discussion

# Discussion

*These findings suggest that LAD is associated with a modest, if any, effect on survival for early-stage endometrial cancer*

- Propensity/Regression analysis demonstrated improved survival
- Instrumental Variable analysis did not
  - Unmeasured confounding factors may underlie reported association of survival

# Discussion

- Several other trials with similar results
- People continue to question results
  - Quality of LAD
  - Power of study
- If LAD is not directly associated with survival, the procedure provides data regarding adjuvant therapy
  - Potentially avoiding treatment of lower-risk women

*“Our data suggest that at the population level, any survival benefit from LAD is likely very small”*

Questions?

Thank you!